Wedbush Has Bullish Forecast for Immunome FY2024 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Equities researchers at Wedbush raised their FY2024 earnings estimates for shares of Immunome in a report issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($2.11) for the year, up from their previous forecast of ($2.23). Wedbush has a “Outperform” rating and a $33.00 price target on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.13) per share. Wedbush also issued estimates for Immunome’s Q4 2024 earnings at ($0.70) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.77) EPS, FY2026 earnings at ($2.70) EPS and FY2027 earnings at ($2.11) EPS.

A number of other analysts also recently commented on IMNM. Piper Sandler dropped their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Stephens assumed coverage on shares of Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price target on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $28.83.

Immunome Trading Down 0.5 %

IMNM stock opened at $9.39 on Monday. Immunome has a 52 week low of $6.93 and a 52 week high of $30.96. The company has a market capitalization of $586.10 million, a price-to-earnings ratio of -1.16 and a beta of 1.82. The firm’s 50-day moving average is $12.91 and its two-hundred day moving average is $13.70.

Insider Transactions at Immunome

In other news, CFO Max Rosett sold 14,380 shares of Immunome stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total value of $230,223.80. Following the transaction, the chief financial officer now owns 47,476 shares of the company’s stock, valued at $760,090.76. The trade was a 23.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several hedge funds have recently made changes to their positions in IMNM. Swiss National Bank acquired a new position in shares of Immunome in the 1st quarter worth approximately $1,762,000. Sei Investments Co. acquired a new stake in shares of Immunome during the first quarter valued at approximately $469,000. Vanguard Group Inc. raised its holdings in shares of Immunome by 16.1% during the first quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock valued at $49,847,000 after acquiring an additional 279,712 shares during the period. Acadian Asset Management LLC raised its holdings in shares of Immunome by 602.1% during the first quarter. Acadian Asset Management LLC now owns 133,438 shares of the company’s stock valued at $3,292,000 after acquiring an additional 114,433 shares during the period. Finally, EntryPoint Capital LLC raised its holdings in shares of Immunome by 21,864.0% during the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after acquiring an additional 5,466 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.